The President of the Italian Society of Neonatology (Sin) Calabria, Gianfranco Scarpelliexpressed a heartfelt thanks to the President of the Region Roberto Occhiuto For having defined, among the first regions in Italy, the purchasing procedures of Nersevimab, a drug necessary for prophylaxis against syncitial respiratory virus infections (VRS).
“An important preventive medicine strategy is made – he said Shoes – which allows you to intercept serious diseases before their clinical manifestation, with significant benefits for the childish population ».
Since April 2025, Sin Calabria has released an information to the parents of all infants at the birth points of the region to raise awareness of the importance of prevention of bronchiolitis from VRS through the Norsevimab, whose administration will begin from October.
A praise was also addressed to the manager of the prevention sector of the Health and Welfare Department, Francesco Luciafor completing the procedures necessary for the acquisition of the drug in record time.
Therefore, from 1 October 2025, prophylaxis will begin with the administration of Nrsevimab to all children born from 1 April 2025 to 30 September 2025 at the vaccine centers of the ASP in Cosenza or at their family pediatrician. In addition, all infants born from 1 October 2025 onwards and until 31 March 2026 will be subjected to prophylaxis in their respective birth points.